unlike those commonly observed for placebo effects, as placebo effects often wane as treatment time increases. The observation that vitamin D improves mood is consistent with several prior studies. [6] [7] [8] For example, Jorde et al. 6 reported that a low serum level of 25(OH)D among participants in the fifth Tromsø study in northern Norway was significantly associated with psychological depression. Lansdowne and Provost 7 found that supplementation with cholecalciferol (400-800 IU/day) for 5 days during late winter resulted in a significantly enhanced positive affect. Similarly, Vieth et al. 8 found improved well-being after vitamin D 3 supplementation for 3 months.
In summary, oral cholecalciferol (vitamin D 3 ) at a dose of 50-100 mg/day did not result in hematological improvements in low-and INT-1-risk MDS patients, despite significant increases in 25(OH)D levels. This drug was well tolerated at these doses. Our study suggests that cholecalciferol (vitamin D 3 ) has a significant positive effect on mood. Given the low toxicity and low cost of oral cholecalciferol, further dose escalations appear warranted. The prevalence of immune thrombocytopenia (IT) in chronic lymphocytic leukemia (CLL) is around 2%. This makes IT the most frequent autoimmune disorder during CLL, second only to hemolytic anemia. 1 Autoreactive antibodies are not usually produced by the neoplastic clone.
2 So far it is unknown if mutational status of immunoglobulin heavy-chain variableregion (IgVH) gene has any influence on the risk of developing autoimmune phenomena during the course of the disease. IgVH DNA sequence analysis, introduced since 2000 in the diagnostic work-up of our patients with CLL, revealed an apparent higher risk for un-mutated CLL to develop IT during the course of the disease. To verify this observation we performed a casecontrol study in the entire cohort of 680 CLL patients consecutively referred to our Department from 1st January 1995 to 1st January 2005. We evaluated IgVH status and VH gene repertoire in all the 20 CLL patients who developed IT at presentation or during the course of the disease, and in 20 CLL controls without IT. Cases fulfilled all the following criteria: rapid (o2 weeks) and severe fall (at least half of the initial level and below 100 Â 10 3 /ml) of the platelet count; normal or augmented number of megakariocytes in bone marrow in the absence of extensive (490%) lymphoid infiltration; no or limited splenomegaly; no recent (o1 month) cytotoxic treatment. Controls were matched for gender, age and RAI stage at diagnosis, year of diagnosis, and length of follow-up to adjust for the time at risk of developing thrombocytopenia. Cases and controls met the diagnostic criteria for CLL of the National Cancer Institute. DNA was obtained from peripheral blood or bone marrow specimens at diagnosis or at the time of matching. Sequences were aligned to IMGT and V-BASE directories and analyzed using DNAPLOT and IMGT/VQUEST software. Sequences differing more than 2% from the corresponding germ-line gene were considered mutated. Median follow-up time from diagnosis of CLL was 64 months. All cases, except one, presented with RAI stage 0 or 1, median time to thrombocytopenia was 13 months (range 0-147), median platelet count at nadir was 12 Â 10 3 /ml (range 1-70), with all patients except one requiring specific therapy for thrombocytopenia. An exceedingly high prevalence of un-mutated IgVH was found in patients with IT (16 out of 20, 80%). For comparison only six out of 20 (30%) of controls showed un-mutated IgVH, a figure consistent with their early RAI stage. 3 The odds ratio of developing IT in un-mutated CLL could be estimated as 9.33 (95% CI 1.82-52.6, P ¼ 0.001). In addition, in patients who developed IT we found an excess of VH1 and VH3 families without any case of VH4, usually reported as one of the most frequent gene assortment in CLL 4, 5 (P ¼ 0.0004, by w 2 test, see Table 1 ).
Although the results of this study warrant further confirmation from multicenter investigations because of the low incidence of IT in CLL, for the first time they strongly correlate the development of IT to IgVH un-mutated status in CLL patients. One could speculate that in the un-mutated CLL group, which is characterized by a peculiar antibody reactivity and by a more aggressive clinical course, 6 there would be a major failure in controlling the emergence of auto-antibodies from normal B cells. Acute myeloid leukemia (AML) is a clonal hematopoietic disorder that develops as a result of cumulative genetic and epigenetic events that affect key regulatory genes conferring a proliferative growth and survival advantage. Both intrinsic and acquired chemotherapeutic resistance remain as major limitations in the successful treatment of AML. 1 Evidence suggest that drug resistance mechanisms other than multidrug resistance phenotype are involved, such as reduced intracellular concentrations of ara-CTP, the active triphosphorylated form of Ara-C. 
